Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment
2016 ASCO Annual Meeting
Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.
James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).
James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).
Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).
Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).